Karmanos Cancer Institute | Strategic Alliance Partners

Karmanos Cancer Institute is a leader in transformative cancer care, research and education through courage, commitment and compassion. Our vision is a world free of cancer. As part of McLaren Health Care, Karmanos is the largest provider of cancer care and research in the state of Michigan. For more than 75 years, our administrative and research headquarters, along with our premier specialty cancer hospital, have been located in downtown Detroit. Our 15 network sites throughout the state deliver market-leading cancer care and clinical trials conveniently to the communities where many of our patients live. Karmanos is recognized by the National Cancer Institute as one of the best cancer centers in the nation with a comprehensive cancer center designation. Our academic partnership with the Wayne State University School of Medicine provides the framework for cancer research and education – defining new standards of care and improving survivorship. For more information, call 1-800-KARMANOS (800-527-6266) or visit www.karmanos.org. Follow Karmanos on Facebook, Twitter, LinkedIn and YouTube.Karmanos Cancer Institute is a leader in transformative cancer care, research and education through courage, commitment and compassion. As part of McLaren Health Care, Karmanos is the largest provider of cancer care and research in the state of Michigan. For more than 75 years, our administrative and research headquarters, along with our premier specialty cancer hospital, have been located in downtown Detroit. Our 15 network sites throughout the state deliver market-leading cancer care and clinical trials conveniently to the communities where many of our patients live. Karmanos is recognized by the National Cancer Institute as one of the best cancer centers in the nation.

YouTube Channel

Connect with us:

Latest from Karmanos Cancer Institute

Deol on the Importance of a Well-Rounded Fellowship Experience

September 26, 2022

Podcast

Dr Deol discusses what he wants his trainees to take from the fellowship program he directs, how his colleagues help fellows find jobs, and how he helps fellows deal with grief.

Fellows’ Passion Keeps Deol Sharp and Up to Date

September 14, 2022

Article

Abhinav Deol, MD, discusses how Karmanos Cancer Institute prepares trainees for their first job and helps them handle negative situations and deal with grief.

CAR T-cell Therapy Establishes Prominent Role Across Hematologic Malignancies

August 20, 2022

Article

In recent years, cellular immune therapies such as chimeric antigen receptor T-cell therapy have significantly improved response rates for various hematological malignancies.

Karmanos Faculty Share Experiences and Career Insights as Women in Oncology

May 30, 2022

Podcast

Drs Mamdani, Assad, and Robinette discuss the changes in the culture of oncology today compared with when they first started their careers, the challenges they experienced along the way, and advice they would share with up-and-coming oncologists based on what they know now.

Dr. Yang on the Current Treatment Landscape in MCL

May 26, 2022

Video

Jay Yang, MD, discusses the current treatment landscape of mantle cell lymphoma.

Dr. Deol on Collaboration in the Administration of CAR T-cell Therapy

May 20, 2022

Video

Abhinav Deol, MD, discusses the importance of communication and collaboration in CAR T-cell therapy.

Dr. Deol on CAR T-Cell Therapy in Earlier Lines of Therapy in Cancer Care

May 03, 2022

Video

Abhinav Deol, MD, discusses shifting CAR T-cell therapy to earlier lines of therapy in cancer care.

Personalized Medicine Evolves With CDK4/6 Inhibitors, Immunotherapy, and ADCs in Breast Cancer

April 21, 2022

Article

Hadeel Assad, MD, discussed how CDK4/6 inhibitors have been implemented into practice and provided updates on key clinical trials in HER2-positive breast cancer and triple-negative breast cancer.

Institutional Perspectives in Cancer- Breast Cancer: Chaired by Hadeel Assad, MD

April 06, 2022

Video

Institutional Perspectives in Cancer- Breast Cancer: Chaired by Hadeel Assad, MD

REGN5458 Shows Promising ORR and Safety in Relapsed/Refractory Myeloma

February 09, 2022

Article

Jeffrey Zonder, MD, discusses his presentation at the 2021 ASH Annual Meeting on the impact of the phase 1/2 study utilizing REGN5458 in multiple myeloma.

Chemotherapy-Free Options Expand the Scope of Treatment in Leukemia and Lymphoma

October 12, 2021

Article

Across the paradigms of leukemias and lymphomas, novel therapies—such as BTK inhibitors, PI3K inhibitors, time-limited therapies, and even CAR T-cell therapies—have transformed the treatment of patients and prolonged survival without the need for chemotherapy.

OncLive State of Science Summit: Leukemia/Lymphoma: Chaired by Dipenkumar Modi, MD

September 28, 2021

Article